

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1208DXJ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
 NEWS 2 Jan 25 BLAST(R) searching in REGISTRY available in STN on the Web  
 NEWS 3 Jan 29 FSTA has been reloaded and moves to weekly updates  
 NEWS 4 Feb 01 DKILIT now produced by FIZ Karlsruhe and has a new update frequency  
 NEWS 5 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02  
 NEWS 6 Mar 08 Gene Names now available in BIOSIS  
 NEWS 7 Mar 22 TOXLIT no longer available  
 NEWS 8 Mar 22 TRCTHERMO no longer available  
 NEWS 9 Mar 28 US Provisional Priorities searched with P in CA/CAPLUS and USPATFULL  
 NEWS 10 Mar 28 LIPINSKI/CALC added for property searching in REGISTRY  
 NEWS 11 Apr 02 PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.  
 NEWS 12 Apr 08 "Ask CAS" for self-help around the clock  
 NEWS 13 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area  
 NEWS 14 Apr 09 ZDB will be removed from STN  
 NEWS 15 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB  
 NEWS 16 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS  
 NEWS 17 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
 NEWS 18 Apr 22 Federal Research in Progress (FEDRIP) now available  
 NEWS 19 Jun 03 New e-mail delivery for search results now available  
 NEWS 20 Jun 10 MEDLINE Reload  
 NEWS 21 Jun 10 PCTFULL has been reloaded

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,  
 CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),  
 AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
 NEWS INTER General Internet Information  
 NEWS LOGIN Welcome Banner and News Items  
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:18:11 ON 21 JUN 2002

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:18:29 ON 21 JUN 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 19 JUN 2002 HIGHEST RN 432491-02-6  
DICTIONARY FILE UPDATES: 19 JUN 2002 HIGHEST RN 432491-02-6

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES  
for more information. See STN Note 27, Searching Properties in the CAS  
Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

	SINCE FILE	TOTAL
	ENTRY	SESSION
=> fil .search		
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	0.38	0.59

FILE 'MEDLINE' ENTERED AT 09:18:47 ON 21 JUN 2002

FILE 'CAPLUS' ENTERED AT 09:18:47 ON 21 JUN 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 09:18:47 ON 21 JUN 2002  
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'USPATFULL' ENTERED AT 09:18:47 ON 21 JUN 2002  
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 09:18:47 ON 21 JUN 2002  
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

```
=> s alpha.sub.v.beta.sub.3
4 FILES SEARCHED...
L1      488 ALPHA.SUB.V.BETA.SUB.3

=> s l1 and (chelate? or ligand?)
L2      291 L1 AND (CHELATE? OR LIGAND?)

=> s l2 and (target?)
L3      217 L2 AND (TARGET?)

=> s l3 and (metal or metals)
L4      115 L3 AND (METAL OR METALS)

=> s l4 and (peptide?)
L5      110 L4 AND (PEPTIDE?)

=> s l5 and angiogene?
L6      78 L5 AND ANGIOGENE?
```

```
=> dup rem l6
PROCESSING COMPLETED FOR L6
L7          78 DUP REM L6 (0 DUPLICATES REMOVED)

=> s l6 and (link?)
L8          70 L6 AND (LINK?)

=> dup rem l8
PROCESSING COMPLETED FOR L8
L9          70 DUP REM L8 (0 DUPLICATES REMOVED)

=> d ibib ab 1-
YOU HAVE REQUESTED DATA FROM 70 ANSWERS - CONTINUE? Y/(N):y
```

L9 ANSWER 1 OF 70 USPATFULL  
ACCESSION NUMBER: 2002:149165 USPATFULL  
TITLE: Cycloalkyl alkanolic acids as integrin receptor antagonists  
INVENTOR(S): Khanna, Ish Kumar, Libertyville, IL, UNITED STATES  
Clare, Michael, Skokie, IL, UNITED STATES  
Gasielki, Alan F., Vernon Hills, IL, UNITED STATES  
Rogers, Thomas, Ballwin, MO, UNITED STATES  
Chen, Barbara, Northbrook, IL, UNITED STATES  
Russell, Mark, Gurnee, IL, UNITED STATES  
Lu, Hwang-Fun, Manchester, MO, UNITED STATES

NUMBER	KIND	DATE
US 2002077321	A1	20020620
US 2001-882186	A1	20010615 (9)

PATENT INFORMATION:  
APPLICATION INFO.:  
NUMBER DATE  
US 2000-211781P 20000615 (60)

PRIORITY INFORMATION: US 2000-211781P 20000615 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Pharmacia Corporation, Corporate Patent Dept., 800 N. Lindbergh, Mail Zone 04E, St. Louis, MO, 63167  
NUMBER OF CLAIMS: 65  
EXEMPLARY CLAIM: 1  
LINE COUNT: 3069

AB The present invention relates to a class of compounds represented by the

Formula I ##STR1##

or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the .alpha..sub .v.beta..sub.3 and/or .alpha..sub.v.beta..sub.5 integrin.

L9 ANSWER 3 OF 70 USPATFULL  
ACCESSION NUMBER: 2002:141514 USPATFULL  
TITLE: Hydroxy acid integrin antagonists  
INVENTOR(S): Rogers, Thomas, Ballwin, MO, UNITED STATES  
Penning, Thomas D., Elmhurst, IL, UNITED STATES  
Jiang, Lan, Ballwin, MO, UNITED STATES  
Devadas, Balekudru, Chesterfield, MO, UNITED STATES  
Ruminiski, Peter, Ballwin, MO, UNITED STATES  
VanCamp, Jennifer, Glencoe, MO, UNITED STATES  
Yuan, Chester, Thousand, CA, UNITED STATES

NUMBER	KIND	DATE
US 2002072500	A1	20020613
US 2001-963927	A1	20010926 (9)

PATENT INFORMATION: US 2002072500 A1 20020613  
APPLICATION INFO.: US 2001-963927 A1 20010926 (9)

PRIORITY INFORMATION: US 2000-235616P 20000927 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Rachel Polater, Pharmacia Corporation Patent Department, Mail Zone 04E, 800 N. Lindbergh, St. Louis, MO, 63167  
NUMBER OF CLAIMS: 7  
EXEMPLARY CLAIM: 1  
LINE COUNT: 1977

AB The present invention relates to a class of compounds represented by the

Formula I. ##STR1##

or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the .alpha..sub .v.beta..sub.3 and/or the .alpha..sub.v.beta..sub.5 integrin.

L9 ANSWER 2 OF 70 USPATFULL  
ACCESSION NUMBER: 2002:141531 USPATFULL  
TITLE: Bicyclic alphavbeta3 antagonists  
INVENTOR(S): Khanna, Ish Kumar, Libertyville, IL, UNITED STATES  
Yu, Yi, Glenview, IL, UNITED STATES  
Devadas, Balekudru, Chesterfield, MO, UNITED STATES  
Lu, Hwang-Fun, Ballwin, MO, UNITED STATES  
Chandrakumar, Nizal S., Vernon Hills, IL, UNITED STATES

STATES Huff, Renee M., Park Ridge, IL, UNITED STATES  
STATES Dessi, Bipinchandra N., Vernon Hills, IL, UNITED STATES  
Nagarajan, Srinivasan Raj, Chesterfield, MO, UNITED STATES

NUMBER	KIND	DATE
US 2002072518	A1	20020613
US 2001-942174	A1	20010829 (9)

PATENT INFORMATION: US 2002072518 A1 20020613  
APPLICATION INFO.: US 2001-942174 A1 20010829 (9)

PRIORITY INFORMATION: US 2000-228693P 20000829 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Pharmacia Corporation, Corporate Patent Department, 800 N. Lindbergh Blvd., Main Zone 04E, St. Louis, MO, 63167  
NUMBER OF CLAIMS: 16  
EXEMPLARY CLAIM: 1  
LINE COUNT: 2625

AB The present invention relates to a class of compounds represented by the

Formula I ##STR1##

or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the .alpha..sub .v.beta..sub.3 and/or .alpha..sub.v.beta..sub.5 integrin.

L9 ANSWER 4 OF 70 USPATFULL  
ACCESSION NUMBER: 2002:140862 USPATFULL  
TITLE: Targeted therapeutic agents  
INVENTOR(S): Li, King Chuen, Bethesda, MD, UNITED STATES  
Bednarski, Mark David, Los Altos, CA, UNITED STATES  
Wartchow, Charles A., San Francisco, CA, UNITED STATES  
Pease, John S., Los Altos, CA, UNITED STATES  
DeChene, Neal E., Morgan Hill, CA, UNITED STATES  
Trulson, Julie, San Jose, CA, UNITED STATES  
Shen, Zhi Min, Palo Alto, CA, UNITED STATES

NUMBER	KIND	DATE
US 2002071843	A1	20020613
US 2001-976254	A1	20011011 (9)

PATENT INFORMATION: US 2002071843 A1 20020613  
APPLICATION INFO.: US 2001-976254 A1 20011011 (9)

PRIORITY INFORMATION: US 2000-239684P 20001011 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SWANSON & BRATSCHEIN L.L.C., 1745 SHEA CENTER DRIVE, SUITE 330, HIGHLANDS RANCH, CO, 80129  
NUMBER OF CLAIMS: 32  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 27 Drawing Page(s)  
LINE COUNT: 2866

AB Therapeutic and imaging agents which are comprised of a targeting entity, a therapeutic or treatment entity and a linking carrier are provided. The linking carrier imparts additional advantages to the therapeutic agents, which are not provided by conventional linking methods. Preferred agents of the present invention comprise a lipid construct, vesicle, liposome, or polymerized liposome. In some cases, the therapeutic or treatment entity is a radioisotope, chemotherapeutic agent, prodrug, toxin, or gene encoding a protein that exhibits cell toxicity. Preferably, the agent is further comprised of a stabilizing entity that imparts additional advantages to the therapeutic or imaging agent.

L9 ANSWER 5 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:133837 USPATFULL  
 TITLE: Peptide-mimetic compounds containing RGD sequence useful as integrin inhibitors  
 INVENTOR(S): Scolastico, Carlo, Milan, ITALY  
 Giannini, Giuseppe, Pomezia, ITALY

NUMBER	KIND	DATE
US 2002068695	A1	20020606
US 2001-777013	A1	20010206 (9)

PATENT INFORMATION: Continuation-in-part of Ser. No. US 1999-366198, filed on 4 Aug 1999, GRANTED, Pat. No. US 6235877

NUMBER	DATE
IT 1998-MI2477	19981116

PRIORITY INFORMATION: Utility  
 DOCUMENT TYPE: APPLICATION  
 FILE SEGMENT: NIXON & VANDERHYE P.C., 8th Floor, 1100 North Glebe Road, Arlington, VA, 22201-4714  
 LEGAL REPRESENTATIVE: NIXON & VANDERHYE P.C., 8th Floor, 1100 North Glebe Road, Arlington, VA, 22201-4714

NUMBER OF CLAIMS: 20  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 12 Drawing Page(s)  
 LINE COUNT: 2309

AB The present invention discloses compounds of formula (I) ##STR1##

wherein n is the number 0, 1 or 2. There are also disclosed processes for the preparation of said compounds, together with methods for treating pathologies related to an altered .alpha..sub.v.beta..sub.3 integrin-mediated cell attachment, in particular wherein the inhibition of angiogenesis is desired, for example in tumors, also associated with metastasis.

L9 ANSWER 6 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:126754 USPATFULL  
 TITLE: Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion  
 INVENTOR(S): Peyman, Anuschirwan, Kelkheim, GERMANY, FEDERAL REPUBLIC OF  
 Will, David William, Schwalbach, GERMANY, FEDERAL REPUBLIC OF  
 Knolle, Jochen, Kriftel, GERMANY, FEDERAL REPUBLIC OF  
 Scheunemann, Karlheinz, Liederbach, GERMANY, FEDERAL REPUBLIC OF  
 Carniato, Denis, Marcoussis, FRANCE  
 Gourvest, Jean-Francois, Souilly, FRANCE  
 Gadek, Thomas R., Oakland, CA, UNITED STATES  
 McDowell, Robert, San Francisco, CA, UNITED STATES  
 Bodary, Sarah Catherine, San Bruno, CA, UNITED STATES  
 Cuthbertson, Robert Andrew, Victoria, AUSTRALIA

NUMBER	KIND	DATE
US 2002065271	A1	20020530
US 2001-972190	A1	20011009 (9)

PATENT INFORMATION: Division of Ser. No. US 2000-564988, filed on 5 May 2000, PATENTED

NUMBER	DATE
US 1998-72313P	19980123 (60)

PRIORITY INFORMATION: Utility  
 DOCUMENT TYPE: APPLICATION  
 FILE SEGMENT: POLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007  
 LEGAL REPRESENTATIVE: WASHINGTON, DC, 20007

NUMBER OF CLAIMS: 22  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 2261

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Sulfonamide derivatives, their physiologically tolerable salts and their

prodrugs according to the present invention are vitronectin receptor antagonists and inhibitors of cell adhesion, as well as inhibit bone resorption by osteoclasts. These derivatives, salts and prodrugs are pharmaceutically active compounds useful in the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. Processes for the preparation of the sulfonamide derivatives according to the present invention, the use of these derivatives as pharmaceutically active ingredients, and pharmaceutical preparations comprising these derivatives also are disclosed.

L9 ANSWER 7 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:119921 USPATFULL  
 TITLE: Vitronectin receptor antagonist pharmaceuticals  
 INVENTOR(S): Harris, Thomas D., Salem, NH, UNITED STATES  
 Rajopadhye, Milind, Westford, MA, UNITED STATES

NUMBER	KIND	DATE
US 2002061909	A1	20020523
US 2001-948390	A1	20010907 (9)

PATENT INFORMATION: Continuation of Ser. No. US 1999-465300, filed on 17 Dec 1999, PENDING

NUMBER	DATE
US 1998-112732P	19981218 (60)

PRIORITY INFORMATION: Utility  
 DOCUMENT TYPE: APPLICATION  
 FILE SEGMENT: DuPont Pharmaceuticals Company, c/o E. I. duPont de Nemours and Company, Legal Patents, 1007 Market Street, Wilmington, DE, 19898  
 LEGAL REPRESENTATIVE: DuPont Pharmaceuticals Company, c/o E. I. duPont de Nemours and Company, Legal Patents, 1007 Market Street, Wilmington, DE, 19898

NUMBER OF CLAIMS: 57  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 7403

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes novel compounds of the formula:

(Q).sub.d--L.sub.n--C.sub.h,

useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an

optional

linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

L9 ANSWER 8 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:85600 USPATFULL  
 TITLE: Lactone integrin antagonists  
 INVENTOR(S): Ruminiski, Peter, Ballwin, MO, UNITED STATES  
 Penning, Thomas D., Elmhurst, IL, UNITED STATES  
 Jiang, Lan, Ballwin, MO, UNITED STATES  
 Devadas, Balekudru, Chesterfield, MO, UNITED STATES  
 Rogers, Thomas, Ballwin, MO, UNITED STATES  
 VanCamp, Jennifer, Glencoe, MO, UNITED STATES  
 Yuan, Chester, Thousand, CA, UNITED STATES

NUMBER	KIND	DATE
US 2002045645	A1	20020418
US 2001-963926	A1	20010926 (9)

PATENT INFORMATION: Utility  
 APPLICATION INFO.: US 2001-963926 A1 20010926 (9)

NUMBER	DATE
US 2000-241633P	20001019 (60)
US 2000-235617P	20000927 (60)

PRIORITY INFORMATION: Utility  
 DOCUMENT TYPE: APPLICATION  
 FILE SEGMENT: Rachel A. Polster, Pharmacia Corporation Patent Department, Mail Zone 04E, 800 N. Lindbergh, St. Louis, MO, 63167  
 LEGAL REPRESENTATIVE: Rachel A. Polster, Pharmacia Corporation Patent Department, Mail Zone 04E, 800 N. Lindbergh, St. Louis, MO, 63167

NUMBER OF CLAIMS: 7  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 2059

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a class of compounds represented by the

Formula I. ##STR1##

or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the .alpha..sub.v.beta..sub.3 and/or the .alpha..sub.v.beta..sub.5 integrin.

L9 ANSWER 9 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:78225 USPATFULL  
 TITLE: Vitronectin receptor antagonist pharmaceuticals  
 INVENTOR(S): Harris, Thomas D., Salem, NH, UNITED STATES  
 Rajopadhye, Milind, Westford, MA, UNITED STATES

NUMBER	KIND	DATE
US 2002041878	A1	20020411
US 2001-948807	A1	20010907 (9)

PATENT INFORMATION: Continuation of Ser. No. US 1999-465300, filed on 17 Dec 1999, PENDING

NUMBER	DATE
US 1998-112732P	19981218 (60)

PRIORITY INFORMATION: Utility  
 DOCUMENT TYPE: APPLICATION  
 FILE SEGMENT: Peter L. Dolan, DuPont Pharmaceuticals Company, c/o E. I. duPont de Nemours and Company, 1007 Market Street, Wilmington, DE, 19898  
 LEGAL REPRESENTATIVE: 57  
 NUMBER OF CLAIMS: 1  
 EXEMPLARY CLAIM: 7398  
 LINE COUNT: 1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes novel compounds of the formula:

(Q).sub.d-L.sub.n-C.sub.h,

useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an

optional

linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

L9 ANSWER 10 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:72996 USPATFULL  
 TITLE: Vitronectin receptor antagonist  
 INVENTOR(S): Harding, Dirk, Malvern, PA, UNITED STATES  
 PATENT ASSIGNEE(S): SmithKline Beecham Corporation (U.S. corporation)

NUMBER	KIND	DATE
US 2002040136	A1	20020404
US 2001-996141	A1	20011128 (9)

PATENT INFORMATION: Continuation of Ser. No. US 2000-509142, filed on 22 Mar 2000, ABANDONED A 371 of International Ser. No. WO 1998-US19949, filed on 24 Sep 1998,  
 Mar

UNKNOWN

NUMBER	DATE
US 1997-59832P	19970924 (60)

PRIORITY INFORMATION: Utility  
 DOCUMENT TYPE: APPLICATION  
 FILE SEGMENT: GLAXOSMITHKLINE, Corporate Intellectual Property - UW2220, P.O. Box 1539, King of Prussia, PA, 19406-0939  
 LEGAL REPRESENTATIVE: 29  
 NUMBER OF CLAIMS: 1  
 EXEMPLARY CLAIM: 1449  
 LINE COUNT: 1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula (I) is disclosed which is a vitronectin receptor antagonist and is useful in the treatment of osteoporosis: ##STR1##

or a pharmaceutically acceptable salt thereof.

L9 ANSWER 11 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:43683 USPATFULL  
 TITLE: 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors  
 INVENTOR(S): Boschelli, Diane Harris, New City, NY, UNITED STATES  
 Wang, Yanong, Nanuet, NY, UNITED STATES  
 Boschelli, Frank Charles, New City, NY, UNITED STATES  
 Berger, Dan Maarten, New City, NY, UNITED STATES  
 Zhang, Man, Bayside, NY, UNITED STATES  
 Powell, Dennis William, Cortlandt Manor, NY, UNITED STATES  
 Ye, Pei, Nanuet, NY, UNITED STATES  
 Yamashita, Ayako, Englewood, NJ, UNITED STATES  
 Demorin, Frenel Pils, Thousand Oaks, CA, UNITED STATES  
 Wu, Biqi, Nanuet, NY, UNITED STATES  
 Tsou, Hwei-Ru, New City, NY, UNITED STATES  
 Overbeek-Klumpers, Elsebe Geraldine, BK Bergentheim, NETHERLANDS  
 Winsner, Allan, Ardsley, NY, UNITED STATES  
 PATENT ASSIGNEE(S): American Home Products Corporation, Madison, NJ, UNITED STATES (U.S. corporation)

NUMBER	KIND	DATE
US 2002026052	A1	20020228
US 2001-820070	A1	20010328 (9)

PATENT INFORMATION: US 2000-219322P 20000328 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: Egon E. Berg, American Home Products Corporation, Patent Law Department, Five Giralda Farms, Madison, NJ, 07940  
 NUMBER OF CLAIMS: 145  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 15941  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides compounds of Formula (I), having the structure ##STR1##

where T, Z, X, A, R.sup.1, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, R.sup.4, and n are defined herein, or a pharmaceutically acceptable salt

thereof which are useful as antineoplastic agents and in the treatment of osteoporosis and polycystic kidney disease.

L9 ANSWER 12 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:32565 USPATFULL  
 TITLE: Vitronectin receptor antagonist  
 INVENTOR(S): Bondinell, William E., Wayne, PA, UNITED STATES  
 PATENT ASSIGNEE(S): SmithKline Beecham Corporation (U.S. corporation)

NUMBER	KIND	DATE
US 2002019387	A1	20020214
US 2001-956682	A1	20010920 (9)

PATENT INFORMATION: Continuation of Ser. No. US 2000-509184, filed on 21 Mar 2000, PENDING A 371 of International Ser. No. WO 1998-US19987, filed on 24 Sep 1998, UNKNOWN

NUMBER	DATE
US 1997-59867P	19970924 (60)

PRIORITY INFORMATION: Utility  
 DOCUMENT TYPE: APPLICATION  
 FILE SEGMENT: GLAXOSMITHKLINE, Corporate Intellectual Property - UW2220, P.O. Box 1539, King of Prussia, PA, 19406-0939  
 LEGAL REPRESENTATIVE: 29  
 NUMBER OF CLAIMS: 1  
 EXEMPLARY CLAIM: 1237  
 LINE COUNT: 1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula (I) is disclosed which is a vitronectin receptor antagonist and is useful in the treatment of osteoporosis: ##STR1##

or a pharmaceutically acceptable salt thereof.

L9 ANSWER 13 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:26835 USPATFULL  
 TITLE: QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST  
 PHARMACEUTICALS  
 INVENTOR(S): HARRIS, THOMAS DAVID, SALEM, NH, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002015680	A1	20020207
APPLICATION INFO.:	US 1999-281209	A1	19990330 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-80150P	19980331 (60)
	US 1998-112715P	19981218 (60)
	US 1998-112829P	19981218 (60)
	US 1998-112732P	19981218 (60)
	US 1998-112831P	19981218 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: Dupont Pharmaceuticals Company, Legal Department -  
 Patents, 1007 Market Street, Wilmington, DE, 19898

NUMBER OF CLAIMS: 48  
 EXEMPLARY CLAIMS: 1  
 LINE COUNT: 6696  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes novel compounds of the formula:

(Q).sub.d--L.sub.n--C.sub.h,

useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

L9 ANSWER 14 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:3593 USPATFULL  
 TITLE: PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS  
 INVENTOR(S): RAJOPADHYE, MILIND, WESTFORD, MA, UNITED STATES  
 EDWARDS, D. SCOTT, BURLINGTON, MA, UNITED STATES  
 HARRIS, THOMAS D., SAMEL, NH, UNITED STATES  
 HAMINWAY, STUART J., LOWELL, MA, UNITED STATES  
 LIU, SHUANG, CHELMSFORD, MA, UNITED STATES  
 SINGH, PRAHLAD R., ARLINGTON, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002001566	A1	20020103
APPLICATION INFO.:	US 1999-281474	A1	19990330 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-80150P	19980331 (60)
	US 1998-112715P	19981218 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: DAVID H. VANCE, DUPONT PHARMACEUTICALS COMPANY, C/O E.  
 I. DU PONT DE NEMOURS AND CO., LEGAL - PATENTS-1007  
 MARKET STREET, WILMINGTON, DE, 19898

NUMBER OF CLAIMS: 51  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 5872  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes novel compounds of the formula:

(Q).sub.d--L.sub.n--C.sub.h,

useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

L9 ANSWER 15 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:14940 USPATFULL  
 TITLE: Cancer treatment methods using antibodies to aminophospholipids  
 INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States  
 Ran, Sophia, Dallas, TX, United States  
 PATENT ASSIGNEE(S): Board of Regents, The University of Texas System,  
 Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6406693	B1	20020618
APPLICATION INFO.:	US 1999-351543		19990712 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-110608P	19981202 (60)
	US 1998-92672P	19980713 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Bansal, Geetha P.  
 LEGAL REPRESENTATIVE: Williams, Morgan and Amerson

NUMBER OF CLAIMS: 63  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 6 Drawing Figure(s); 3 Drawing Page(s)  
 LINE COUNT: 7541

AB Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression in vivo. This invention therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach.

L9 ANSWER 16 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:136772 USPATFULL  
 TITLE: Affinity labeling libraries with tagged leaving group  
 INVENTOR(S): Krantz, Alexander, Menlo Park, CA, United States  
 Hanel, Arthur M., San Francisco, CA, United States  
 Huang, Wolin, Foster City, CA, United States  
 PATENT ASSIGNEE(S): ConjuChem, Inc., Montreal, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6403324	B1	20020611
APPLICATION INFO.:	US 1998-42234		19980313 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-714754, filed on 16 Sep 1996, now abandoned  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Ponnaluri, Padmaashri  
 LEGAL REPRESENTATIVE: Morrison & Foerster LLP  
 NUMBER OF CLAIMS: 15  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)  
 LINE COUNT: 940

AB Methods and compositions are provided for identifying compounds having affinity to a target site. The method provides for the affinity group to be a leaving group from a reactive functionality capable of forming a covalent bond to the target site. One can combine the compound comprising the target site with the library, and assay for the resulting composition of the leaving groups. The leaving groups having the highest concentration can be identified

as the groups having the binding highest affinity for the target site. The selected compounds may then be used for labeling the target molecule, particularly where the target molecule is naturally found in a complex mixture, such as a physiological fluid, like blood. By affinity labeling in vivo, the lifetime of physiologically active entities can be greatly enhanced by becoming bound to long lived blood components. The covalently bound entity may also serve as an antagonist or agonist of a particular binding proteins or as an enzyme inhibitor.

L9 ANSWER 17 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:129978 USPATFULL  
 TITLE: Cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists  
 INVENTOR(S): Wehner, Volkmar, Sandberg, GERMANY, FEDERAL REPUBLIC OF  
 OF Knolle, Jochen, Kriftel, GERMANY, FEDERAL REPUBLIC OF  
 Stiltz, Hans Ulrich, Frankfurt, GERMANY, FEDERAL REPUBLIC OF  
 Gourvest, Jean-Francois, Biberonne, FRANCE  
 Carniato, Denis, Clamart, FRANCE  
 Gadek, Thomas Richard, Oakland, CA, United States  
 McDowell, Robert, San Francisco, CA, United States  
 Pitti, Robert Maurice, El Cerrito, CA, United States  
 Bodary, Sarah Catherine, San Bruno, CA, United States  
 PATENT ASSIGNEE(S): Aventis Pharma S.A., Frankfurt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)  
 NUMBER KIND DATE  
 PATENT INFORMATION: US 6399620 B1 20020604  
 APPLICATION INFO.: US 2000-606080 20000629 (9)  
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-899503, filed on 24 Jul 1997, now abandoned

NUMBER DATE  
 PRIORITY INFORMATION: DE 1996-19629816 19960724  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Coleman, Brenda  
 LEGAL REPRESENTATIVE: Foley & Lardner  
 NUMBER OF CLAIMS: 14  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)  
 LINE COUNT: 1650  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are described cycloalkyl derivatives of the formula (I)

R.sup.1--Y--A--B--D--E--F--G (I)

in which R.sup.1, Y, A, B, D, E, F and G have the meaning indicated herein, their preparation and their use as medicaments. The compounds according to the invention can be used as vitronectin receptor antagonists and as inhibitors of bone resorption.

L9 ANSWER 18 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:116292 USPATFULL  
 TITLE: Imidoguanidine derivatives, preparation method, use as medicines  
 INVENTOR(S): Carniato, Denis, Cagnes sur Mer, FRANCE  
 Gourvest, Jean-Francois, Claye-Souilly, FRANCE  
 Ruxer, Jean-Marie, Issy les Moulineaux, FRANCE  
 Knolle, Jochen, Kriftel, GERMANY, FEDERAL REPUBLIC OF  
 Peyman, Anuschirwan, Kelkheim, GERMANY, FEDERAL REPUBLIC OF  
 Bodary, Sarah C., San Bruno, CA, United States  
 Gadek, Thomas R., Oakland, CA, United States  
 PATENT ASSIGNEE(S): Aventis Pharma S.A., FRANCE (non-U.S. corporation)  
 Genentech, Inc., United States (U.S. corporation)  
 NUMBER KIND DATE  
 PATENT INFORMATION: US 6391904 B1 20020521  
 APPLICATION INFO.: WO 2000031044 20000602  
 US 2001-856693 20010629 (9)  
 WO 1999-FR2880 19991123  
 20010629 PCT 371 date

NUMBER DATE  
 PRIORITY INFORMATION: FR 1998-14780 19981124  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Stockton, Laura L.  
 LEGAL REPRESENTATIVE: Bierman, Muserlian and Lucas  
 NUMBER OF CLAIMS: 12  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)  
 LINE COUNT: 1528  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula ##STR1##

where the substituents are defined in the specification and its pharmaceutically acceptable salts and produgs thereof useful as antagonists of vitronectin receptors.

L9 ANSWER 19 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:109033 USPATFULL  
 TITLE: Vitronectin receptor antagonists, their preparation and their use  
 INVENTOR(S): Wehner, Volkmar, Sandberg, GERMANY, FEDERAL REPUBLIC OF  
 OF Stiltz, Hans Ulrich, Frankfurt, GERMANY, FEDERAL REPUBLIC OF  
 Peyman, Anuschirwan, Kelkheim, GERMANY, FEDERAL REPUBLIC OF  
 Knolle, Jochen, Kriftel, GERMANY, FEDERAL REPUBLIC OF  
 Ruxer, Jean-Marie, Issy les Moulineaux, FRANCE  
 Carniato, Denis, Marcoussis, FRANCE  
 Lefrancois, Jean-Michel, Livry Gargan, FRANCE  
 Gadek, Thomas Richard, Oakland, CA, United States  
 McDowell, Robert, San Francisco, CA, United States  
 Hoechst Aktiengesellschaft, Frankfurt am Main, GERMANY,  
 FEDERAL REPUBLIC OF (non-U.S. corporation)  
 Genentech, Inc., San Francisco, CA, United States  
 (U.S. corporation)  
 NUMBER KIND DATE  
 PATENT INFORMATION: US 6387895 B1 20020514  
 APPLICATION INFO.: US 2001-777011 20010206 (9)  
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-412331, filed on 5 Oct 1999, now patented, Pat. No. US 6207663 Division of Ser. No. US 1997-995521, filed on 22 Dec 1997, now patented, Pat. No. US 6011045

NUMBER DATE  
 PRIORITY INFORMATION: DE 1996-19653647 19961220  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Raymond, Richard L.  
 LEGAL REPRESENTATIVE: Foley & Lardner  
 NUMBER OF CLAIMS: 10  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)  
 LINE COUNT: 3251  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds of the formula I

A--B--D--E--F--G (I)

in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as inhibitors of bone resorption.

L9 ANSWER 20 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:81463 USPATFULL  
 TITLE: .alpha.-nu..beta.3 integrin antagonists in combination with chemotherapeutic agents  
 INVENTOR(S): Cunningham, Jay, 3733 N. Bell Ave., Chicago, IL, United States 60618  
 Gordon, Gary B., 3282 University Ave., Highland Park, IL, United States 60035  
 Nickols, G. Allen, 2690 Lenexa Ln., Wentzville, MO, United States 63385  
 Westlin, William F., 15989 Woodlet Park Ct., Chesterfield, MO, United States 63017  
 Rogers, Thomas Edward, 755 Trago Creek Dr., Ballwin, MO, United States 63021  
 Ruminski, Peter Gerrard, 7687 Pierside Dr., Dardenne Prairie, MO, United States 63366

NUMBER KIND DATE  
 PATENT INFORMATION: US 6372719 B1 20020416  
 APPLICATION INFO.: US 1999-262725 19990304 (9)  
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1998-34270, filed on 4 Mar 1998, now abandoned  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Goldberg, Jerome D.  
 LEGAL REPRESENTATIVE: Scrivner, Alan, Polster, Rachel  
 NUMBER OF CLAIMS: 13  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)  
 LINE COUNT: 2306  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds of the formula ##STR1##

and pharmaceutically acceptable salts and isomers thereof administered in combination with chemotherapeutic agents.



L9 ANSWER 21 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:75564 USPATFULL  
 TITLE: Integrin-linked kinase and its uses  
 INVENTOR(S): Dedhar, Shoukat, Vancouver, CANADA  
 Hannigan, Greg, Ontario, CANADA  
 PATENT ASSIGNEE(S): Sunnybrook Health Science Centre, Toronto, CANADA  
 (non-U.S. corporation)

NUMBER	KIND	DATE
US 6369205	B1	20020409

PATENT INFORMATION: US 2000-566906 20000509 (9)  
 APPLICATION INFO.: Division of Ser. No. US 1999-390425, filed on 3 Sep 1999  
 RELATED APPLM. INFO.: 1999 Continuation-in-part of Ser. No. US 1997-955841, filed on 21 Oct 1997, now patented, Pat. No. US 6013782  
 Continuation-in-part of Ser. No. US 1996-752345, filed on 19 Nov 1996, now abandoned

NUMBER	DATE
US 1995-9074P	19951221 (60)

PRIORITY INFORMATION: US 1995-9074P 19951221 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Clark, Deborah J. R.  
 ASSISTANT EXAMINER: Chen, Shin-Lin  
 LEGAL REPRESENTATIVE: Sherwood, Pamela J., Bozicevic, Field & Francis LLP  
 NUMBER OF CLAIMS: 5  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 25 Drawing Figure(s); 23 Drawing Page(s)  
 LINE COUNT: 3200  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Methods for isolating ILK genes are provided. The ILK nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.

L9 ANSWER 23 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:19060 USPATFULL  
 TITLE: Antibody conjugate compositions for selectively inhibiting VEGF  
 INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States  
 Brekken, Rolf A., Seattle, WA, United States  
 PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6342221	B1	20020129

PATENT INFORMATION: US 2000-561108 20000428 (9)  
 APPLICATION INFO.: US 2000-561108 20000428 (9)

NUMBER	DATE
US 1999-131432P	19990428 (60)

PRIORITY INFORMATION: US 1999-131432P 19990428 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Chan, Christina Y.  
 ASSISTANT EXAMINER: Huynh, Phuong N.  
 LEGAL REPRESENTATIVE: Williams, Morgan and Amerson  
 NUMBER OF CLAIMS: 68  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 7 Drawing Figure(s); 4 Drawing Page(s)  
 LINE COUNT: 10492  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.

L9 ANSWER 22 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:70095 USPATFULL  
 TITLE: Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian CD97 .alpha. subunit  
 INVENTOR(S): Kelly, Kathleen, North Potomac, MD, United States  
 PATENT ASSIGNEE(S): The United States of America as represented by the Secretary of the Department of Health and Human Services, Washington, DC, United States (U.S. government)

NUMBER	KIND	DATE
US 6365712	B1	20020402

PATENT INFORMATION: US 6365712 B1 20020402  
 WO 9817796 19980430  
 APPLICATION INFO.: US 1999-284819 19990820 (9)  
 WO 1997-US19772 19971024  
 19990820 PCT 371 date

NUMBER	DATE
US 1996-27871P	19961025 (60)

PRIORITY INFORMATION: US 1996-27871P 19961025 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Huff, Sheela  
 ASSISTANT EXAMINER: Harris, Alana M.  
 LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP  
 NUMBER OF CLAIMS: 9  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 6 Drawing Figure(s); 5 Drawing Page(s)  
 LINE COUNT: 3805  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Isolated proteins comprising the T-cell surface antigen CD97 .alpha. are provided. Compositions and methods for making and detecting CD97 .alpha. are also provided. Further, the invention provides diagnostic and therapeutic methods and compositions for medical conditions involving CD97.

L9 ANSWER 24 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:19058 USPATFULL  
 TITLE: Antibody compositions for selectively inhibiting VEGF  
 INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States  
 Brekken, Rolf A., Seattle, WA, United States  
 PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6342219	B1	20020129

PATENT INFORMATION: US 2000-561500 20000428 (9)  
 APPLICATION INFO.: US 2000-561500 20000428 (9)

NUMBER	DATE
US 1999-131432P	19990428 (60)

PRIORITY INFORMATION: US 1999-131432P 19990428 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Chan, Christina Y.  
 ASSISTANT EXAMINER: Huynh, Phuong N.  
 LEGAL REPRESENTATIVE: Williams, Morgan and Amerson  
 NUMBER OF CLAIMS: 50  
 EXEMPLARY CLAIM: 20  
 NUMBER OF DRAWINGS: 7 Drawing Figure(s); 4 Drawing Page(s)  
 LINE COUNT: 10403  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.

L9 ANSWER 25 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:13996 USPATFULL  
 TITLE: Guanidine derivatives as inhibitors of cell adhesion  
 INVENTOR(S): Peyman, Anuschirwan, Melkheim, GERMANY, FEDERAL  
 REPUBLIC OF  
 Knolle, Jochen, San Francisco, CA, United States  
 Scheunemann, Karl-Heinz, Liederbach, GERMANY, FEDERAL  
 REPUBLIC OF  
 Will, David William, Kriftel, GERMANY, FEDERAL  
 REPUBLIC  
 OF  
 Carniato, Denis, Marcoussis, FRANCE  
 Gourvest, Jean-Francois, Claye Souilly, FRANCE  
 Gadek, Thomas R., Oakland, CA, United States  
 Bodary, Sarah Catherine, San Bruno, CA, United States  
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Frankfurt, GERMANY,  
 FEDERAL REPUBLIC OF (non-U.S. corporation)  
 Genentech, Inc., South San Francisco, CA, United  
 States  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6340679	B1	20020122
APPLICATION INFO.:	US 2000-502577		20000211 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1999-102916	19990213
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Rao, Deepak	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	1625	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to acylguanidine derivatives of the formula I ##STR1##

in which R.sup.1, R.sup.2, R.sup.4, Ar, X and n have the meanings indicated in the claims, their physiologically tolerable salts and their

prodrugs. The compounds of the formula I are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion. They inhibit, for example, bone resorption by osteoclasts and are suitable for the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example osteoporosis. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceutical preparations, and pharmaceutical preparations comprising them.

L9 ANSWER 27 OF 70 USPATFULL  
 ACCESSION NUMBER: 2001:194406 USPATFULL  
 TITLE: Osteopontin-derived chemotactic and inhibitory agents and uses therefor  
 INVENTOR(S): Ashkar, Samy, Boston, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001036921	A1	20011101
APPLICATION INFO.:	US 2000-729873	A1	20001205 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2000-US10344	20000417
	US 1999-129764P	19990415 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109  
 NUMBER OF CLAIMS: 39  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 1763

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel osteopontin-derived chemotactic and inhibitory agents are described. Methods of using these agents are also described.

L9 ANSWER 26 OF 70 USPATFULL  
 ACCESSION NUMBER: 2002:9751 USPATFULL  
 TITLE: Integrin-linked kinase and its uses  
 INVENTOR(S): Dedhar, Shoukat, Vancouver, CANADA  
 Hannigan, Greg, Ontario, CANADA  
 PATENT ASSIGNEE(S): Sunnybrook Health Science Centre, Toronto, CANADA  
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6338958	B1	20020115
APPLICATION INFO.:	US 1999-390425		19990903 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-35706, filed on 5 Mar 1998, now patented, Pat. No. US 6001622		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-9074P	19951221 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Clark, Deborah J. R.	
ASSISTANT EXAMINER:	Chen, Shin-Lin	
LEGAL REPRESENTATIVE:	Sherwood, Pamela J., Bozicevic, Field & Francis LLP	
NUMBER OF CLAIMS:	4	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 23 Drawing Page(s)	
LINE COUNT:	3203	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for isolating ILK genes are provided. The ILK nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.

L9 ANSWER 28 OF 70 USPATFULL  
 ACCESSION NUMBER: 2001:155774 USPATFULL  
 TITLE: Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors  
 INVENTOR(S): Wehner, Volkmar, Sandberg, Germany, Federal Republic of  
 Knolle, Jochen, Kriftel, Germany, Federal Republic of  
 Stitz, Hans Ulrich, Frankfurt, Germany, Federal Republic of  
 Carniato, Denis, Marcoussis, France  
 Gourvest, Jean-Francois, Clay Souilly, France  
 Gadek, Tom, Oakland, CA, United States  
 McDowell, Robert, San Francisco, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001021708	A1	20010913
APPLICATION INFO.:	US 2001-798995	A1	20010306 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-821253, filed on 20 Mar 1997, GRANTED, Pat. No. US 6218415		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19610919	19960320
	DE 1996-19626701	19960703
	DE 1996-19635522	19960902

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: Michele M. Simkin, FOLEY & LARDNER, Suite 500, 3000 K Street, N.W., Washington, DC, 20007-5109  
 NUMBER OF CLAIMS: 8  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 3304

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to 5-membered ring heterocycles of the formula I, ##STR1##

in which E, F, G, W, Y and Z have the meaning given in the patent claims, to their preparation and to their use as medicaments.

The novel compounds are used as vitronectin receptor antagonists and as inhibitors of bone reabsorption.

L9 ANSWER 29 OF 70 USPATFULL  
 ACCESSION NUMBER: 2001:123579 USPATFULL  
 TITLE: Vitronectin receptor antagonists, their preparation and their use  
 INVENTOR(S): Wehner, Volkmar, Sandberg, Germany, Federal Republic of  
 Stiltz, Hans Ulrich, Frankfurt, Germany, Federal Republic of  
 Peyman, Anuschirwan, Kelkheim, Germany, Federal Republic of  
 Scheunemann, Karlheinz, Liederbach, Germany, Federal Republic of  
 Ruxer, Jean-Marie, Issy les Moulineaux, France  
 Carniato, Denis, Marcoussais, France  
 Lefrancois, Jean-Michel, Livry Gargan, France  
 Gadek, Thomas Richard, Oakland, CA, United States  
 McDowell, Robert, San Francisco, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001011087	A1	20010802
APPLICATION INFO.:	US 2001-778755	A1	20010208 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-412314, filed on 5 Oct 1999, GRANTED, Pat. No. US 6218387 Division of Ser. No. US 1997-995522, filed on 22 Dec 1997, GRANTED, Pat. No. US 5990145		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19653645	19961220
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Michele M. Simkin, FOLEY & LARDNER, Washington Harbour, 3000 K Street, N.W., Suite 500, Washington, DC, 20007-5109	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2527	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Vitronectin receptor antagonists, their preparation and their use The present invention relates to compounds of the formula 1,

A--B--D--E--F--G (I)

in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as inhibitors of bone resorption.

L9 ANSWER 31 OF 70 USPATFULL  
 ACCESSION NUMBER: 2001:211038 USPATFULL  
 TITLE: Structurally determined cyclic metallo-constructs and applications  
 INVENTOR(S): Sharma, Shubb D., Plainsboro, NJ, United States  
 PATENT ASSIGNEE(S): Palatin Technologies, Inc., Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6331285	B1	20011218
APPLICATION INFO.:	US 1999-464358		19991215 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-660697, filed on 5 Jun 1996, now patented, Pat. No. US 6027711		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Jones, Dameron L.		
LEGAL REPRESENTATIVE:	Slusher, Stephen A. Peacock, Myers & Adams		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	20 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	4839		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A metallo-construct, which may be a peptide, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or combinatorial chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The peptide constructs are of the general formula:

R.sub.1 --X--R.sub.2

where X is a plurality of amino acids and includes a complexing backbone for complexing metal ions, so that substantially all of the valences of the metal ion are satisfied upon complexation of the metal ion with X, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R.sub.1 and R.sub.2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R.sub.1 or R.sub.2 or both have a structure forming the balance of the conformationally constrained global secondary structure. All or a portion of the global secondary structure, which may be synchrologic or rhegnylogic, may form a ligand or mimic a known biological-function domain. The construct has substantially higher affinity for its target upon labeling with a metal ion.

L9 ANSWER 30 OF 70 USPATFULL  
 ACCESSION NUMBER: 2001:231041 USPATFULL  
 TITLE: Targeted diagnostic/therapeutic agents having more than one different vectors  
 INVENTOR(S): Klaveness, Jo, Oslo, Norway  
 Rongved, P. ang. l. Oslo, Norway  
 H. o alashed.gset, Anders, Oslo, Norway  
 Tolleshaug, Helge, Oslo, Norway  
 Cuthbertson, Alan, Oslo, Norway  
 Hoff, Lars, Oslo, Norway  
 Bryn, Klaus, Oslo, Norway  
 Hellebust, Halldis, Oslo, Norway  
 Solbakken, Magne, Oslo, Norway  
 PATENT ASSIGNEE(S): Nycomed Imaging AS, Oslo, Norway (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6331289	B1	20011218
APPLICATION INFO.:	US 1997-959206		19971028 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-22366	19961028
	GB 1996-22369	19961028
	GB 1997-2195	19970204
	GB 1997-8265	19970424
	GB 1997-11837	19970606
	GB 1997-11839	19970606
	US 1997-49263P	19970606 (60)
	US 1997-49266P	19970607 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Hartley, Michael G.  
 LEGAL REPRESENTATIVE: Bacon & Thomas  
 NUMBER OF CLAIMS: 22  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)  
 LINE COUNT: 4091  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

L9 ANSWER 32 OF 70 USPATFULL  
 ACCESSION NUMBER: 2001:214639 USPATFULL  
 TITLE: Indole vitronectin receptor antagonist  
 INVENTOR(S): Rajopadhye, Milind, Westford, MA, United States  
 Harris, Thomas David, Salem, NH, United States  
 DuPont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6322770	B1	20011127
APPLICATION INFO.:	US 1999-281207		19990330 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Jones, Dameron L.		
LEGAL REPRESENTATIVE:	Dolan, Peter L.		
NUMBER OF CLAIMS:	70		
EXEMPLARY CLAIM:	1		
LINE COUNT:	6228		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention d ribs novel compounds of the formula:

(Q).sub.d --L.sub.n --C.sub.h,

useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

L9 ANSWER 33 OF 70 USPATFULL  
 ACCESSION NUMBER: 2001:197016 USPATFULL  
 TITLE: Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion  
 INVENTOR(S): Feyman, Anuschirwan, Kelkheim, Germany, Federal Republic of  
 Will, David William, Schwalbach, Germany, Federal Republic of  
 Knolle, Jochen, Kriftel, Germany, Federal Republic of  
 Scheunemann, Karlheinz, Liederbach, Germany, Federal Republic of  
 Carniato, Denis, Marcoussis, France  
 Courvest, Jean Francois, Souilly, France  
 Gadek, Thomas R., Oakland, CA, United States  
 McDowell, Robert, San Francisco, CA, United States  
 Bodary, Sarah Catherine, San Bruno, CA, United States  
 Cuthbertson, Robert Andrew, Victoria, Australia  
 Adventis Pharma Deutschland GmbH, Frankfurt, Germany, Federal Republic of (non-U.S. corporation)  
 Genentech, Inc., South San Francisco, CA, United States  
 PATENT ASSIGNEE(S):  
 States  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6313119	B1	20011106
APPLICATION INFO.:	US 2000-564988		20000505 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-235271, filed on 22 Jan 1999, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-72313P	19980123 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Raymond, Richard L.	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2217	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Sulfonamide derivatives, their physiologically tolerable salts and their

prodrugs according to the present invention are vitronectin receptor antagonists and inhibitors of cell adhesion, as well as inhibit bone resorption by osteoclasts. These derivatives, salts and prodrugs are pharmaceutically active compounds useful in the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. Processes for the preparation of the sulfonamide derivatives according to the present invention, the use of these derivatives as pharmaceutically active ingredients, and pharmaceutical preparations comprising these derivatives also are disclosed.

L9 ANSWER 35 OF 70 USPATFULL  
 ACCESSION NUMBER: 2001:179101 USPATFULL  
 TITLE: Isoxazoline fibrinogen receptor antagonists  
 INVENTOR(S): Smallheer, Joanne M., Landenberg, PA, United States  
 Wang, Shuaige, West Chester, PA, United States  
 Jadhav, Prabhakar Kondaji, Wilmington, DE, United States  
 PATENT ASSIGNEE(S): DuPont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6303609	B1	20011016
APPLICATION INFO.:	US 1999-442682		19991118 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-108835P	19981118 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Patel, Sudhaker B.	
LEGAL REPRESENTATIVE:	Larsen, Scott K., Belfield, Jing S.	
NUMBER OF CLAIMS:	55	
EXEMPLARY CLAIM:	1	
LINE COUNT:	6537	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to novel isoxazolines and isoxazoles of formula (I): ##STR1##

or a pharmaceutically acceptable salt or prodrug form thereof. The invention relates to novel isoxazolines which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds,

alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

L9 ANSWER 34 OF 70 USPATFULL  
 ACCESSION NUMBER: 2001:196603 USPATFULL  
 TITLE: Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids  
 INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States  
 Ran, Sophia, Dallas, TX, United States  
 Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6312694	B1	20011106
APPLICATION INFO.:	US 1999-351457		19990712 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-92589P	19980713 (60)
	US 1998-110600P	19981202 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Bonsal, Geetha P.	
LEGAL REPRESENTATIVE:	Williams, Morgan & Amerson	
NUMBER OF CLAIMS:	50	
EXEMPLARY CLAIM:	1,2,3,4	
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	8243	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.

L9 ANSWER 36 OF 70 USPATFULL  
 ACCESSION NUMBER: 2001:131335 USPATFULL  
 TITLE: Thiophene integrin inhibitors  
 INVENTOR(S): Labrecque, Denis, Laval, Canada  
 Attardo, Giorgio, Laval, Canada  
 Bubenik, Monica, Montreal, Canada  
 Chan, Laval, Kirkland, Canada  
 Charron, Sylvie, Montreal, Canada  
 Denis, Real, Laval, Canada  
 Falardeau, Guy, Laval, Canada  
 Lamothe, Serge, Boisbriand, Canada  
 Preville, Patrice, Blainville, Canada  
 Zacharie, Boulos, Laval, Canada  
 PATENT ASSIGNEE(S): BioChem Pharma Inc., Laval, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6274620	B1	20010814
APPLICATION INFO.:	US 2000-588574		20000607 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-137726P	19990607 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Lambkin, Deborah C.	
LEGAL REPRESENTATIVE:	Arent Fox Kintner Plotkin & Kahn PLLC	
NUMBER OF CLAIMS:	38	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2618	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention comprises compounds that are effective inhibitors of integrins, particularly .alpha.v.beta.3 and .alpha.v.beta.5 integrins. Particularly, the compounds are of formula I ##STR1##

and pharmaceutically acceptable salts thereof wherein X,Y.sub.1 W, R1 to R5, A and B are defined according to the disclosure herein.

L9 ANSWER 37 OF 70 USPATFULL  
 ACCESSION NUMBER: 2001:116526 USPATFULL  
 TITLE: Targeted ultrasound contrast agents  
 INVENTOR(S): Klaveness, Jo, Oslo, Norway  
 Rongved, P.ang.1, Oslo, Norway  
 L.o slashed.vhaug, Dagfinn, Oslo, Norway  
 PATENT ASSIGNEE(S): Nycomed Imaging AS, Oslo, Norway (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6264917	B1	20010724
APPLICATION INFO.:	US 1997-958993		19971028 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-22366	19961028
	GB 1996-22367	19961028
	GB 1996-22368	19961028
	GB 1997-699	19970115
	GB 1997-8265	19970424
	GB 1997-11842	19970606
	GB 1997-11846	19970606
	US 1997-49264P	19970607 (60)
	US 1997-49268P	19970607 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Hartley, Michael G.  
 LEGAL REPRESENTATIVE: Bacon & Thomas  
 NUMBER OF CLAIMS: 17  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)  
 LINE COUNT: 5477

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, having reporters comprising gas-filled microbubbles stabilised by monolayers of film-forming surfactants, the reporter being coupled or linked to at least one vector.

L9 ANSWER 38 OF 70 USPATFULL  
 ACCESSION NUMBER: 2001:111808 USPATFULL  
 TITLE: Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors  
 INVENTOR(S): Klaveness, Jo, Oslo, Norway  
 Rongved, P.ang.1, Oslo, Norway  
 H.o slashed.gæet, Anders, Oslo, Norway  
 Tolleshaug, Helge, Oslo, Norway  
 N.a.e buttet.vested, Anne, Oslo, Norway  
 Hellebust, Halldis, Oslo, Norway  
 Hoff, Lars, Oslo, Norway  
 Cuthbertson, Alan, Oslo, Norway  
 L.o slashed.vhaug, Dagfinn, Oslo, Norway  
 Solbakken, Magne, Oslo, Norway  
 PATENT ASSIGNEE(S): Nycomed Imaging AS, Oslo, Norway (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6261537	B1	20010717
APPLICATION INFO.:	US 1997-960054		19971029 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-958993, filed on 28 Oct 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-22366	19961028
	GB 1996-22367	19961028
	GB 1996-22368	19961028
	GB 1997-699	19970115
	GB 1997-8265	19970424
	GB 1997-11842	19970606
	GB 1997-11846	19970606
	US 1997-49264P	19970607 (60)
	US 1997-49265P	19970607 (60)
	US 1997-49268P	19970607 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Hartley, Michael G.  
 LEGAL REPRESENTATIVE: Bacon & Thomas, Fichter, Richard E.  
 NUMBER OF CLAIMS: 22  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)  
 LINE COUNT: 5614

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, having reporters comprising gas-filled microbubbles stabilised by monolayers of film-forming surfactants, the reporter being coupled or linked to at least one vector.

L9 ANSWER 39 OF 70 USPATFULL  
 ACCESSION NUMBER: 2001:97624 USPATFULL  
 TITLE: Stabilized nucleic acid compositions and methods of preparation and use thereof  
 INVENTOR(S): Chen, Xian, San Diego, CA, United States  
 Ma, Chenglie, San Diego, CA, United States  
 D'Andrea, Mark J., Carlsbad, CA, United States  
 PATENT ASSIGNEE(S): Selective Genetics, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251599	B1	20010626
APPLICATION INFO.:	US 1998-187727		19981106 (9)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Houtteman, Scott W.  
 LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC  
 NUMBER OF CLAIMS: 82  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 15 Drawing Figure(s); 9 Drawing Page(s)  
 LINE COUNT: 2084

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Preparations of nucleic acid condensates and compositions containing such condensates are provided. The nucleic acid condensates are in the form of small particles that are stable when subjected to destabilizing conditions such as lyophilizing, freeze-thawing, and prolonged liquid storage. These compositions may be used to deliver nucleic acid to cells.

L9 ANSWER 40 OF 70 USPATFULL  
 ACCESSION NUMBER: 2001:55991 USPATFULL  
 TITLE: Inhibitors or bone reabsorption and antagonists of vitronectin receptors  
 INVENTOR(S): Wehner, Volkmar, Sandberg, Germany, Federal Republic of  
 Knolle, Jochen, Krieffel, Germany, Federal Republic of  
 Stiltz, Hans Ulrich, Frankfurt, Germany, Federal Republic of  
 Carniato, Denis, Marcoussis, France  
 Gourvest, Jean-Francois, Claye Souilly, France  
 Gadek, Tom, Oakland, CA, United States  
 McDowell, Robert, San Francisco, CA, United States  
 Hoechst Aktiengesellschaft, Frankfurt am Main, Germany,  
 Federal Republic of (non-U.S. corporation)  
 Genetech, Inc., San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6218415	B1	20010417
APPLICATION INFO.:	US 1997-821253		19970320 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19610919	19960320
	DE 1996-19626701	19960703
	DE 1996-19635522	19960902

DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Higel, Floyd D.  
 ASSISTANT EXAMINER: Sackey, Ebenezer  
 LEGAL REPRESENTATIVE: Foley & Lardner  
 NUMBER OF CLAIMS: 8  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 3290

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors

The present invention relates to 5-membered ring heterocycles of the formula I, ##STR1##

in which E, F, G, W, Y and Z have the meaning given in the patent claims, to their preparation and to their use as medicaments.

The novel compounds are used as vitronectin receptor antagonists and as inhibitors of bone reabsorption.

L9 ANSWER 41 OF 70 USPATFULL  
 ACCESSION NUMBER: 2001:55963 USPATFULL  
 TITLE: Vitronectin receptor antagonists, their preparation and their use  
 INVENTOR(S): Wehner, Volkmar, Sandberg, Germany, Federal Republic of  
 Stiltz, Hans Ulrich, Frankfurt, Germany, Federal Republic of  
 Peyman, Anuschirwan, Kelkheim, Germany, Federal Republic of  
 Scheunemann, Karlheinz, Liederbach, Germany, Federal Republic of  
 Ruxer, Jean-Marie, Issy les Moulineaux, France  
 Carniato, Denis, Marcoussis, France  
 LeFrancis, Jean-Michel, Livry Gargan, France  
 Gadek, Thomas Richard, Oakland, CA, United States  
 McDowell, Robert, San Francisco, CA, United States  
 Hoechst Aktiengesellschaft, Frankfurt am Main, Germany,  
 Federal Republic of (non-U.S. corporation)  
 Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6218387	B1	20010417
APPLICATION INFO.:	US 1999-412314		19991005 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-995522, filed on 22 Dec 1997, now patented, Pat. No. US 5990145		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19653646	19961220
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Raymond, Richard L.	
ASSISTANT EXAMINER:	Liu, Hoang	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2356	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds of the formula I,

A--B--D--E--F--G (I)

in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as inhibitors of bone resorption.

L9 ANSWER 43 OF 70 USPATFULL  
 ACCESSION NUMBER: 2001:44221 USPATFULL  
 TITLE: Vitronectin receptor antagonists, their preparation and their use  
 INVENTOR(S): Wehner, Volkmar, Sandberg, Germany, Federal Republic of  
 Stiltz, Hans Ulrich, Frankfurt, Germany, Federal Republic of  
 Peyman, Anuschirwan, Kelkheim, Germany, Federal Republic of  
 Knolle, Jochen, Krieffel, Germany, Federal Republic of  
 Ruxer, Jean-Marie, Issy les Moulineaux, France  
 Carniato, Denis, Marcoussis, France  
 LeFrancis, Jean-Michel, Livry Gargan, France  
 Gadek, Thomas Richard, Oakland, CA, United States  
 McDowell, Robert, San Francisco, CA, United States  
 Hoechst Aktiengesellschaft, Frankfurt, am Main, Germany, Federal Republic of (non-U.S. corporation)  
 Genentech, Inc., San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6207663	B1	20010327
APPLICATION INFO.:	US 1999-412331		19991005 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-995521, filed on 22 Dec 1997, now patented, Pat. No. US 6011045		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19653647	19961220
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Raymond, Richard L.	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3388	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Vitronectin receptor antagonists, their preparation and their use

The present invention relates to compounds of the formula I

A--B--D--E--F--G (I)

in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as inhibitors of bone resorption.

L9 ANSWER 42 OF 70 USPATFULL  
 ACCESSION NUMBER: 2001:52058 USPATFULL  
 TITLE: Integrin inhibitor produgs  
 INVENTOR(S): Jadhav, Prabhakar K., Wilmington, DE, United States  
 Batt, Douglas G., Wilmington, DE, United States  
 Hussein, Munir A., Wilmington, DE, United States  
 Pitts, William J., Newark, DE, United States  
 Repta, Arnold J., Wilmington, DE, United States  
 DuPont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6214834	B1	20010410
APPLICATION INFO.:	US 1998-49305		19980327 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-41759P	19970328 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Rao, Deepak R.	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
LINE COUNT:	6833	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to novel heterocycles which are useful as antagonists of the  $\alpha$ .sub.v.beta..sub.3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, to iontophoretic delivery of such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

L9 ANSWER 44 OF 70 USPATFULL  
 ACCESSION NUMBER: 2001:19695 USPATFULL  
 TITLE: Iontophoretic delivery of integrin inhibitors  
 INVENTOR(S): Hussein, Munir A., Wilmington, DE, United States  
 Repta, Arnold J., Greenville, DE, United States  
 DuPont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6185453	B1	20010206
APPLICATION INFO.:	US 1997-877829		19970618 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-20277P	19960619 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Weddington, Kevin E.	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	3193	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to novel methods and devices for iontophoretically administering therapeutic doses of integrin receptor antagonists in a controlled manner through the skin. Such integrin receptor antagonists include but are not limited to antagonists of the  $\text{Ib/IIIa}$  and  $\alpha$ .sub.v.beta..sub.3 integrins and related cell surface adhesive protein receptors. The present invention includes iontophoretic delivery devices comprising integrin inhibitors. Such methods and devices are useful, alone or in combination with other therapeutic agents, for the treatment of thromboembolic disorders, angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

L9 ANSWER 45 OF 70 USPATFULL  
 ACCESSION NUMBER: 2001:4929 USPATFULL  
 TITLE: Chiral-.beta.-amino acid compounds and derivatives thereof  
 INVENTOR(S): Malecha, James W., Libertyville, IL, United States  
 Praher, Thomas P., Chicago, IL, United States  
 PATENT ASSIGNEE(S): G.D. Searle & Co., Chicago, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6172256	B1	20010109
APPLICATION INFO.:	US 1999-261647		19990303 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-34270, filed on 4 Mar 1998, now abandoned		
DOCUMENT TYPE:	Patent		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Geist, Gary		
ASSISTANT EXAMINER:	Khare, D		
LEGAL REPRESENTATIVE:	Kovecevic, Cynthia S.		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1970		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention is directed to a method for the preparation of a chiral .beta.-amino ester of the formula ##STR1##  
 wherein R is lower alkyl; and X and Y are the same or different Cl, Br or I.

L9 ANSWER 46 OF 70 USPATFULL  
 ACCESSION NUMBER: 2000:168146 USPATFULL  
 TITLE: Anti-human .alpha..sub.v .beta..sub.3 and .alpha..sub.v .beta..sub.5 antibodies  
 INVENTOR(S): Jonek, Zdenka Ludmila, SmithKline Beecham Corporation  
 Corporate Intellectual Property-UM2220 P.O. Box 1539, King of Prussia, PA, United States 19406-0939  
 Taylor, Alexander, SmithKline Beecham Corporation  
 Corporate Intellectual Property-UM2220 P.O. Box 1539, King of Prussia, PA, United States 19406-0939  
 Trulli, Stephen H, SmithKline Beecham Corporation  
 Corporate Intellectual Property-UM2220 P.O. Box 1539, King of Prussia, PA, United States 19406-0939  
 Johanson, Kyung O, SmithKline Beecham Corporation  
 Corporate Intellectual Property-UM2220 P.O. Box 1539, King of Prussia, PA, United States 19406-0939

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6160099		20001212
APPLICATION INFO.:	US 1998-199149		19981124 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Huff, Sheela		
ASSISTANT EXAMINER:	Helms, Larry R.		
LEGAL REPRESENTATIVE:	Baumeister, Kirk, King, William T.		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	2245		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to a human .alpha..sub.v subunit-containing heterodimeric integrin receptors and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of disorders mediated by such receptors, such as cancer, in human patients.

L9 ANSWER 47 OF 70 USPATFULL  
 ACCESSION NUMBER: 2000:164081 USPATFULL  
 TITLE: Tissue factor methods and compositions for coagulation and tumor treatment  
 INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States  
 King, Steven W., Foothill Ranch, CA, United States  
 Gao, Boning, Dallas, TX, United States  
 PATENT ASSIGNEE(S): Board Of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6156321		20001205
APPLICATION INFO.:	US 1998-9822		19980120 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-42427P	19970327 (60)
	US 1997-36205P	19970127 (60)
	US 1997-35920P	19970122 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Bansal, Geetha P.  
 LEGAL REPRESENTATIVE: Williams, Morgan and Amerson  
 NUMBER OF CLAIMS: 47  
 EXEMPLARY CLAIM: 1,3  
 NUMBER OF DRAWINGS: 25 Drawing Figure(s); 15 Drawing Page(s)  
 LINE COUNT: 7500

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.

L9 ANSWER 48 OF 70 USPATFULL  
 ACCESSION NUMBER: 2000:137819 USPATFULL  
 TITLE: Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment  
 INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States  
 King, Steven W., Foothill Ranch, CA, United States  
 Gao, Boning, Dallas, TX, United States  
 PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6132729		20001017
APPLICATION INFO.:	US 1998-9217		19980120 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-42427P	19970327 (60)
	US 1997-36205P	19970127 (60)
	US 1997-35920P	19970122 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Bansal, Geetha P.  
 LEGAL REPRESENTATIVE: Williams, Morgan & Amerson  
 NUMBER OF CLAIMS: 46  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 25 Drawing Figure(s); 15 Drawing Page(s)  
 LINE COUNT: 7498

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulation-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.

L9 ANSWER 49 OF 70 USPATFULL  
 ACCESSION NUMBER: 2000:102455 USPATFULL  
 TITLE: Amino benzenepropanoic acid compounds and derivatives thereof  
 INVENTOR(S): Collins, Joe T., Ballwin, MO, United States  
 Devadas, Balekudru, Chesterfield, MO, United States  
 Lu, Hwang-fun, Ballwin, MO, United States  
 Malecha, James W., Libertyville, IL, United States  
 Miyashiro, Julie Marion, Skokie, IL, United States  
 Nagarajan, Srinivasan, Chesterfield, MO, United States  
 Rico, Joseph Gerace, Ballwin, MO, United States  
 Rogers, Thomas E., Ballwin, MO, United States  
 PATENT ASSIGNEE(S): G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6100423		20000808
US 1999-261822		19990303 (9)

PATENT INFORMATION: Continuation-in-part of Ser. No. US 1998-34758, filed on 4 Mar 1998 which is a continuation-in-part of Ser. No. US 1996-713555, filed on 27 Aug 1996

NUMBER	DATE
US 1995-3277P	19950830 (60)

PRIORITY INFORMATION: Utility  
 DOCUMENT TYPE: Granted  
 FILE SEGMENT: Dees, Jose' G.  
 PRIMARY EXAMINER: Qazi, Sabiha N.  
 ASSISTANT EXAMINER: Kovacevic, Cynthia S.  
 LEGAL REPRESENTATIVE: 3  
 NUMBER OF CLAIMS: 1  
 EXEMPLARY CLAIM: 1693  
 LINE COUNT: 1693

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds of the formula ##STR1## where R<sub>sup.1</sub> is BOC or H, R is H or lower alkyl; X and Y are the same or different halo atoms selected from the group consisting of Cl, Br or I and pharmaceutically acceptable salts and isomers thereof.

L9 ANSWER 50 OF 70 USPATFULL  
 ACCESSION NUMBER: 2000:94698 USPATFULL  
 TITLE: Methods and compositions for the specific coagulation of vasculature  
 INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States  
 Edgington, Thomas S., La Jolla, CA, United States  
 BOARD OF REGENTS, The University of Texas System, Austin, TX, United States (U.S. corporation)  
 PATENT ASSIGNEE(S): The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6093399		20000725
US 1995-482369		19950607 (8)

PATENT INFORMATION: Continuation-in-part of Ser. No. US 1994-273567, filed on 11 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-205330, filed on 2 Mar 1994 which is a continuation-in-part of Ser. No. US 1992-846349, filed on 5 Mar 1992, now abandoned

DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Feisee, Lila  
 ASSISTANT EXAMINER: Bansal, Geetha P.  
 LEGAL REPRESENTATIVE: Arnold, White & Durkee, P.C.  
 NUMBER OF CLAIMS: 103  
 EXEMPLARY CLAIM: 1,102  
 NUMBER OF DRAWINGS: 11 Drawing Figure(a); 8 Drawing Page(s)  
 LINE COUNT: 7405

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecific antibody.

L9 ANSWER 51 OF 70 USPATFULL  
 ACCESSION NUMBER: 2000:67747 USPATFULL  
 TITLE: Vitronectin receptor antagonists  
 INVENTOR(S): Miller, William H., Schwenksville, PA, United States  
 Bondinell, William E., Wayne, PA, United States  
 Ku, Thomas Wen Fu, Dresher, PA, United States  
 PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6069159		20000530
WO 9830542		19980716
US 1999-331914		19990629 (9)
WO 1998-US490		19980108
		19990629 PCT 371 date
		19990629 PCT 102(e) date

NUMBER	DATE
US 1997-34026P	19970108 (60)

PRIORITY INFORMATION: Utility  
 DOCUMENT TYPE: Granted  
 FILE SEGMENT: Davis, Zinna Northington  
 PRIMARY EXAMINER: McCarthy, Mary E., Venetianer, Stephne, Kinzig, Charles  
 LEGAL REPRESENTATIVE: M.  
 NUMBER OF CLAIMS: 15  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 1729

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to certain tricyclic compounds that are integrin receptor antagonists.

L9 ANSWER 52 OF 70 USPATFULL  
 ACCESSION NUMBER: 2000:64874 USPATFULL  
 TITLE: Integrin receptor antagonists  
 INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States  
 Meissner, Robert S., Schwenksville, PA, United States  
 Perkins, James J., Churchville, PA, United States  
 PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6066648		20000523
US 1998-212123		19981215 (9)

NUMBER	DATE
US 1997-69910P	19971217 (60)
US 1998-83251P	19980427 (60)
US 1998-92588P	19980713 (60)

PRIORITY INFORMATION: Utility  
 DOCUMENT TYPE: Granted  
 FILE SEGMENT: Richtex, Johann  
 PRIMARY EXAMINER: Keating, Dominic  
 ASSISTANT EXAMINER: Durette, Philippe L., Winokur, Melvin, Sabatelli, Anthony D.  
 LEGAL REPRESENTATIVE: 40  
 NUMBER OF CLAIMS: 1  
 EXEMPLARY CLAIM: 4780  
 LINE COUNT: 4780

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists.

More particularly, the compounds of the present invention are antagonists of the vitronectin receptors .alpha..nu..beta.3 and/or .alpha..nu..beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.



L9 ANSWER 53 OF 70 USPATFULL  
 ACCESSION NUMBER: 2000:53742 USPATFULL  
 TITLE: Method of treatment of arterial and venous thromboembolic disorders  
 INVENTOR(S): Mousa, Shaker Ahmed, Lincoln University, PA, United States  
 PATENT ASSIGNEE(S): Dupont Pharmaceuticals, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6056958		20000502
APPLICATION INFO.:	US 1997-901344		19970728 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-353419, filed on 9 Dec 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	MacMillan, Keith B.		
ASSISTANT EXAMINER:	Wessendorf, T. D.		
LEGAL REPRESENTATIVE:	Vance, David H., Rubin, Kenneth B.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2186		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a method of prevention and/or treatment of thrombosis in a mammal without significantly altering bleeding time or coagulation. This invention further relates to methods of using selective inhibitors of the binding of vitronectin to the .alpha. .sub.v .beta. .sub.3 receptor, alone or in combination with other therapeutic agents, for the inhibition of thrombus formation and/or the treatment of thromboembolic disorders.

L9 ANSWER 54 OF 70 USPATFULL  
 ACCESSION NUMBER: 2000:50562 USPATFULL  
 TITLE: Receptor-mediated gene delivery using bacteriophage vectors  
 INVENTOR(S): Larocca, David, Encinitas, CA, United States  
 Baird, Andrew, San Diego, CA, United States  
 Johnson, Wendy, Encinitas, CA, United States  
 Selective Genetics, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6054312		20000425
APPLICATION INFO.:	US 1997-920396		19970829 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Brusca, John S.		
LEGAL REPRESENTATIVE:	Seed Intellectual Property Law Group		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	2350		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Filamentous phage particles displaying a ligand on their surface are used to deliver a therapeutic gene to a cell. The ligand is a fusion protein with a phage capsid protein, covalently conjugated to phage particles, or complexed with modified phage particles.

L9 ANSWER 55 OF 70 USPATFULL  
 ACCESSION NUMBER: 2000:31039 USPATFULL  
 TITLE: Kits and methods for the specific coagulation of vasculature  
 INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States  
 Edgington, Thomas S., La Jolla, CA, United States  
 PATENT ASSIGNEE(S): The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)  
 Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6036955		20000314
APPLICATION INFO.:	US 1995-479727		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-273567, filed on 11 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-205330, filed on 2 Mar 1994 which is a continuation-in-part of Ser. No. US 1992-846349, filed on 5 Mar 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Feisee, Lila		
ASSISTANT EXAMINER:	Bansal, Geetha P.		
LEGAL REPRESENTATIVE:	Arnold, White & Durkee, L.L.P.		
NUMBER OF CLAIMS:	102		
EXEMPLARY CLAIM:	1.50		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	7366		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecific antibody.

L9 ANSWER 56 OF 70 USPATFULL  
 ACCESSION NUMBER: 2000:21206 USPATFULL  
 TITLE: Structurally determined metallo-constructs and applications  
 INVENTOR(S): Sharma, Shubh D., Albuquerque, NM, United States  
 PATENT ASSIGNEE(S): RhoMed Incorporated, Edison, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6027711		20000222
APPLICATION INFO.:	US 1996-660697		19960605 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-476652, filed on 7 Jun 1995, now patented, Pat. No. US 5891418, issued on 6 Apr 1999		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose G.		
ASSISTANT EXAMINER:	Jones, Dameron		
LEGAL REPRESENTATIVE:	Slusher, Stephen A., Todaro, John C., Peacock, Deborah A.		
NUMBER OF CLAIMS:	38		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	20 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	4915		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A metallo-construct, which may be a peptide, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or combinatorial chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The peptide constructs are of the general formula:

R.sub.1 --X--R.sub.2

where X is a plurality of amino acids and includes a complexing backbone

for complexing metal ions, so that substantially all of the valences of the metal ion are satisfied upon complexation of the metal ion with X, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R.sub.1 and R.sub.2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R.sub.1 or R.sub.2 or both have a structure forming the balance of the conformationally constrained global secondary structure. All or a portion of the global secondary structure, which may be achronologic or rhegnylogic, may form

a ligand or mimic a known biological-function domain. The construct has substantially higher affinity for its target upon labeling with a metal ion.

L9 ANSWER 57 OF 70 USPATFULL  
 ACCESSION NUMBER: 2000:4943 USPATFULL  
 TITLE: Integrin-linked kinase and its uses  
 INVENTOR(S): Dednar, Shoukat, Vancouver, Canada  
 Hannigan, Greg, Ontario, Canada  
 PATENT ASSIGNEE(S): Sunnybrook Health Sciences Center, Ontario, Canada  
 (non-U.S. corporation)

NUMBER	KIND	DATE
US 6013782		20000111
US 1997-955841		19971021 (8)
Continuation-in-part of Ser. No. US 1996-752345, filed on 19 Nov 1996, now abandoned		

NUMBER	DATE
US 1995-9074P	19951221 (60)

PRIORITY INFORMATION: US 1995-9074P 19951221 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Campbell, Bruce R.  
 ASSISTANT EXAMINER: Chen, Shin-lin  
 LEGAL REPRESENTATIVE: Sherwood, PamelaBozicevic, Field & Francis  
 NUMBER OF CLAIMS: 6  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 5 Drawing Figure(s); 23 Drawing Page(s)  
 LINE COUNT: 2569  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for isolating ILK genes are provided. The ILK nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.

L9 ANSWER 58 OF 70 USPATFULL  
 ACCESSION NUMBER: 2000:4813 USPATFULL  
 TITLE: Meta-azacyclic amino benzoic acid compounds and derivatives thereof  
 INVENTOR(S): Rogers, Thomas E., Ballwin, MO, United States  
 Ruminski, Peter G., Dardenne Prairie, MO, United States  
 States  
 PATENT ASSIGNEE(S): G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6013651		20000111
US 1998-34758		19980304 (9)
Continuation-in-part of Ser. No. US 1996-713555, filed on 27 Aug 1996		

NUMBER	DATE
US 1995-3277P	19950830 (60)

PRIORITY INFORMATION: US 1995-3277P 19950830 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Dees, Jose' G.  
 ASSISTANT EXAMINER: Qazi, Sebiha N.  
 LEGAL REPRESENTATIVE: Kovacevic, Cynthia S.  
 NUMBER OF CLAIMS: 36  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 2002  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds of the formula ##STR1## and pharmaceutically acceptable salts and isomers thereof.

L9 ANSWER 59 OF 70 USPATFULL  
 ACCESSION NUMBER: 2000:1888 USPATFULL  
 TITLE: Vitronectin receptor antagonists, their preparation and their use  
 INVENTOR(S): Wehner, Volkmar, Sandberg, Germany, Federal Republic of  
 Stiltz, Hans Ulrich, Frankfurt, Germany, Federal Republic of  
 Peyman, Anuschirwan, Kelkheim, Germany, Federal Republic of  
 Knolle, Jochen, Kriftel, Germany, Federal Republic of  
 Ruxer, Jean-Marie, Issy les Moulineaux, France  
 Carniato, Denis, Marcoussis, France  
 Lefrancois, Jean-Michel, Livry Gargan, France  
 Gadek, Thomas Richard, Oakland, CA, United States  
 McDowell, Robert, San Francisco, CA, United States  
 Hoechst Aktiengesellschaft, Frankfur am Main, United States (non-U.S. corporation)  
 Genentech, Inc., San Francisco, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6011045		20000104
US 1997-995521		19971222 (8)

NUMBER	DATE
DE 1996-19653647	19961220

PRIORITY INFORMATION: DE 1996-19653647 19961220  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Raymond, Richard L.  
 LEGAL REPRESENTATIVE: Foley & Lardner  
 NUMBER OF CLAIMS: 10  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 3262  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds of the formula I

A--B--D--E--F--G (I)

in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as inhibitors of bone resorption.

L9 ANSWER 60 OF 70 USPATFULL  
 ACCESSION NUMBER: 1999:167157 USPATFULL  
 TITLE: Imino compounds, process for their preparation and their use as vitronectin antagonists  
 INVENTOR(S): Wehner, Volkmar, Sandberg, Germany, Federal Republic of  
 Knolle, Jochen, Kriftel, Germany, Federal Republic of  
 Stiltz, Hans Ulrich, Frankfurt, Germany, Federal Republic of  
 Gourvest, Jean-Francois, Claye Souilly, France  
 Carniato, Denis, Clamart, France  
 Gadek, Thomas Richard, Oakland, CA, United States  
 McDowell, Robert, San Francisco, CA, United States  
 Pittli, Robert Maurice, El Cerrito, CA, United States  
 Bodary, Sarah Catherine, San Bruno, CA, United States  
 Hoechst Aktiengesellschaft, Frankfurt, Germany, Republic of (non-U.S. corporation)

NUMBER	KIND	DATE
US 6005117		19991221
US 1997-899887		19970724 (8)

NUMBER	DATE
DE 1996-19629817	19960724

PRIORITY INFORMATION: DE 1996-19629817 19960724  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Higel, Floyd D.  
 LEGAL REPRESENTATIVE: Foley & Lardner  
 NUMBER OF CLAIMS: 17  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 1629  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are described imino derivatives of formula (I)

R.sup.1 --Y--A--B--D--E--F--G (I)

their preparation and their use as medicaments. The compounds according to the invention may be used as vitronectin receptor antagonists and as inhibitors of bone resorption.

L9 ANSWER 61 OF 70 USPATFULL  
 ACCESSION NUMBER: 1999:166596 USPATFULL  
 TITLE: Methods for the specific coagulation of vasculature  
 INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States  
 Edgington, Thomas S., La Jolla, CA, United States  
 PATENT ASSIGNEE(S): Board of Regents, The University of Texas System,  
 Austin, TX, United States (U.S. corporation)  
 The Scripps Research Institute, La Jolla, CA, United  
 States (U.S. corporation)

NUMBER	KIND	DATE
US 6004555	19991221	
US 1995-487427	19950607 (8)	

PATENT INFORMATION: US 6004555  
 APPLICATION INFO.: US 1995-487427  
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-273567, filed  
 on 11 Jul 1994, now abandoned which is a  
 continuation-in-part of Ser. No. US 1994-205330, filed  
 on 2 Mar 1994 which is a continuation-in-part of Ser.  
 No. US 1992-846349, filed on 5 Mar 1992, now abandoned

DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Feisee, Lila  
 ASSISTANT EXAMINER: Eylar, Yvonne  
 LEGAL REPRESENTATIVE: Arnold, White & Durkee, P.C.  
 NUMBER OF CLAIMS: 87  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 11 Drawing Figure(s); 8 Drawing Page(s)  
 LINE COUNT: 7393

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Disclosed are various compositions and methods for use in achieving  
 specific blood coagulation. This is exemplified by the specific in vivo  
 coagulation of tumor vasculature, causing tumor regression, through the  
 site-specific delivery of a coagulant using a bispecific antibody.

L9 ANSWER 62 OF 70 USPATFULL  
 ACCESSION NUMBER: 1999:163477 USPATFULL  
 TITLE: Integrin-linked kinase and its use  
 INVENTOR(S): Dedhar, Shoukat, Vancouver, Canada  
 Hannigan, Greg, Ontario, Canada  
 Sunnybrook Health Science Centre, Ontario, Canada  
 (non-U.S. corporation)

NUMBER	KIND	DATE
US 6001622	19991214	
US 1998-35706	19980305 (9)	

PATENT INFORMATION: US 6001622  
 APPLICATION INFO.: US 1998-35706  
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-955841, filed  
 on 21 Oct 1997 which is a continuation-in-part of Ser.  
 No. US 1996-752345, filed on 19 Nov 1996

NUMBER	DATE
US 1995-9074P	19951221 (60)

PRIORITY INFORMATION: US 1995-9074P  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Achutamurthy, Ponnathapu  
 LEGAL REPRESENTATIVE: Bozicevic, Field & Francis LLP, Sherwood, Pamela  
 NUMBER OF CLAIMS: 4  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 21 Drawing Figure(s); 23 Drawing Page(s)  
 LINE COUNT: 3148

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Methods for isolating ILK genes are provided. The ILK nucleic acid  
 compositions find use in identifying homologous or related proteins and  
 the DNA sequences encoding such proteins; in producing compositions  
 that modulate the expression or function of the protein; and in studying  
 associated physiological pathways. In addition, modulation of the gene  
 activity in vivo is used for prophylactic and therapeutic purposes.  
 such as identification of cell type based on expression, and the like.

L9 ANSWER 63 OF 70 USPATFULL  
 ACCESSION NUMBER: 1999:151248 USPATFULL  
 TITLE: Vitronectin receptor antagonists, their preparation  
 and their use  
 INVENTOR(S): Wehner, Volkmar, Sandberg, Germany, Federal Republic  
 of Stiltz, Hans Ulrich, Frankfurt, Germany, Federal  
 Republic of Feymen, Anuschirwan, Kelkheim, Germany, Federal  
 Republic of Scheunemann, Karlheinz, Liederbach, Germany, Federal  
 Republic of Ruxer, Jean-Marie, Issy les Moulineaux, France  
 Carniato, Denis, Marcoussis, France  
 Lefrancois, Jean-Michel, Livry Gargan, France  
 Gadek, Thomas Richard, Oakland, CA, United States  
 McDowell, Robert, San Francisco, CA, United States  
 Hoechst Aktiengesellschaft, Frankfurt Am Main,  
 Germany, Federal Republic of (non-U.S. corporation)  
 Genentech, Inc., South San Francisco, CA, United  
 States (U.S. corporation)

NUMBER	KIND	DATE
US 5990145	19991123	
US 1997-995522	19971222 (8)	

PATENT INFORMATION: US 5990145  
 APPLICATION INFO.: US 1997-995522  
 RELATED APPLN. INFO.: DE 1996-19653645 19961220

PRIORITY INFORMATION: DE 1996-19653645 19961220  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Raymond, Richard L.  
 LEGAL REPRESENTATIVE: Foley & Lardner  
 NUMBER OF CLAIMS: 10  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 2238

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention relates to compounds of the formula I,

A--B--D--E--F--G

(I)

in which A, B, D, E, F and G have the meanings given in the patent  
 claims, to their preparation and to their use as medicaments. The  
 compounds of the invention are used as vitronectin receptor antagonists  
 and as inhibitors of bone resorption.

L9 ANSWER 64 OF 70 USPATFULL  
 ACCESSION NUMBER: 1999:120389 USPATFULL  
 TITLE: Iontophoretic delivery of cell adhesion inhibitors  
 INVENTOR(S): Sage, Burton H., 7001 Jeffrey Dr., Raleigh, NC, United  
 States 27603  
 Bock, Carl Randolph, 1334 Welcome Cir., Durham, NC,  
 United States 17705  
 Green, Philip G., 17G Carlyle Towers South 100 Winston  
 Dr., Cliffside Park, NJ, United States 07010  
 Hussein, Munir A., 619 Andover Rd., Wilmington, DE,  
 United States 19803  
 Repts, Arnold J., 920 Fairborne Ave., Greenville, DE,  
 United States 19807

NUMBER	KIND	DATE
US 5961483	19991005	
US 1997-878493	19970618 (8)	

PATENT INFORMATION: US 5961483  
 APPLICATION INFO.: US 1997-878493  
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-724105, filed  
 on 30 Sep 1996, now abandoned And Ser. No. US  
 1996-724106, filed on 30 Sep 1996, now abandoned

DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Brouillette, D. Gabrielle  
 LEGAL REPRESENTATIVE: Hoffmann & Baron, LLP  
 NUMBER OF CLAIMS: 26  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)  
 LINE COUNT: 6393

AB This invention relates to novel methods and devices for  
 iontophoretically administering therapeutic doses of cell adhesion  
 receptor antagonists in a controlled manner through the skin. Such  
 antagonist compounds include but are not limited to antagonists of the  
 IIb/IIIa and .alpha..sub.v .beta..sub.3 integrins and related cell  
 surface adhesive protein receptors. The present invention includes  
 iontophoretic delivery devices comprising cell adhesion receptor  
 antagonists. Such methods and devices are useful, alone or in  
 combination with other therapeutic agents, for the treatment of  
 thromboembolic disorders, angiogenic disorders, inflammation, bone  
 degradation, cancer metastasis, diabetic retinopathy, restenosis,  
 macular degeneration, and other conditions mediated by cell adhesion  
 and/or cell migration and/or angiogenesis.

L9 ANSWER 65 OF 70 USPATFULL  
 ACCESSION NUMBER: 1999:92317 USPATFULL  
 TITLE: Ionophoretic delivery of cell adhesion inhibitors  
 INVENTOR(S): Sage, Burton H., Raleigh, NC, United States  
 Bock, Carl Randolph, Durham, NC, United States  
 Green, Philip G., Cliffside Park, NJ, United States  
 Becton Dickinson Research Center, Research Triangle  
 Park, NC, United States (U.S. corporation)  
 PATENT ASSIGNEE(S):  
 NUMBER KIND DATE  
 PATENT INFORMATION: US 5935598 19990810  
 APPLICATION INFO.: US 1997-877602 19970618 (8)  
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-724105, filed  
 on 30 Jun 1996, now abandoned And a  
 continuation-in-part of Ser. No. US 1996-724106, filed  
 on 30 Jun 1996, now abandoned  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Dees, Jose' G.  
 ASSISTANT EXAMINER: Shelborne, Kathryn E.  
 LEGAL REPRESENTATIVE: Hoffmann & Baron, LLP  
 NUMBER OF CLAIMS: 27  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)  
 LINE COUNT: 4525

AB This invention relates to novel methods and devices for  
 iontophoretically administering therapeutic doses of cell adhesion  
 receptor antagonists in a controlled manner through the skin. Such  
 antagonist compounds include but are not limited to antagonists of the  
 IIB/IIIA and .alpha..sub.v .beta..sub.3 inter and related cell surface  
 adhesive protein receptors. The present invention includes  
 iontophoretic  
 delivery devices comprising cell adhesion receptor antagonists. Such  
 methods and devices are useful, alone or in combination with other  
 therapeutic agents, for the treatment of thromboembolic disorders,  
 angiogenic disorders, inflammation, bone degradation, cancer  
 metastasis,  
 diabetic retinopathy, restenosis, macular degeneration, and other  
 conditions mediated by cell adhesion and/or cell migration and/or  
 angiogenesis.

L9 ANSWER 66 OF 70 USPATFULL  
 ACCESSION NUMBER: 1999:27746 USPATFULL  
 TITLE: Tissue factor compositions and ligands for  
 the specific coagulation of vasculature  
 INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States  
 Edgington, Thomas S., La Jolla, CA, United States  
 The Scripps Research Institute, La Jolla, CA, United  
 States (U.S. corporation)  
 Board of Regents, The University of Texas System,  
 Austin, TX, United States (U.S. corporation)  
 NUMBER KIND DATE

PATENT INFORMATION: US 5877289 19990302  
 APPLICATION INFO.: US 1995-479733 19950607 (8)  
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-273567, filed  
 on 11 Jul 1994 which is a continuation-in-part of Ser.  
 No. US 1994-205330, filed on 2 Mar 1994, now patented,  
 Pat. No. US 5855866 which is a continuation-in-part of  
 Ser. No. US 1992-846349, filed on 5 Mar 1992  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Feisee, Lila  
 ASSISTANT EXAMINER: Bansal, Geetha P.  
 LEGAL REPRESENTATIVE: Arnold White & Durkee L.L.P.  
 NUMBER OF CLAIMS: 100  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 11 Drawing Figure(s); 8 Drawing Page(s)  
 LINE COUNT: 7148

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Disclosed are various compositions and methods for use in achieving  
 specific blood coagulation. This is exemplified by the specific in vivo  
 coagulation of tumor vasculature, causing tumor regression, through the  
 site-specific delivery of a coagulant using a bispecific antibody.

L9 ANSWER 67 OF 70 USPATFULL  
 ACCESSION NUMBER: 1998:82717 USPATFULL  
 TITLE: Fivemer cyclic peptide inhibitors of diseases  
 involving .alpha..sub.v .beta..sub.3  
 INVENTOR(S): Palladino, Michael A., Olivenhain, CA, United States  
 Lee, Bruce A., San Diego, CA, United States  
 Huse, William D., San Diego, CA, United States  
 Verner, Judith A., Encinitas, CA, United States  
 PATENT ASSIGNEE(S): IXSYS, Incorporated, San Diego, CA, United States  
 (U.S. corporation)  
 NUMBER KIND DATE  
 PATENT INFORMATION: US 5780426 19980714  
 APPLICATION INFO.: US 1995-482107 19950607 (8)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Walsh, Stephen  
 ASSISTANT EXAMINER: Brown, Karen E.  
 LEGAL REPRESENTATIVE: Needle & Rosenberg, P.C.  
 NUMBER OF CLAIMS: 9  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 1944

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention includes non-RGD cyclic peptides that  
 inhibit the function of the integrin receptor, .alpha..sub.v .beta..sub.3. The  
 inventive peptides are between five to about thirty amino  
 acids in length and include the sequence (SEQ ID NO:8),  
 Arg-Cys-Asp-Gly-X.sub.i where X.sub.i is any amino acid, and a  
 five-membered cyclic portion. These non-RGD peptides display  
 surprisingly potent antagonist activity despite the lack of the  
 consensus binding sequence Arg-Gly-Asp, and present opportunities for  
 selective targeting to the .alpha..sub.v .beta..sub.3 receptor.  
 Pharmaceutical compositions and methods of use are also disclosed. The  
 therapeutic uses for the inventive peptides include treating  
 diseases involving .alpha..sub.v .beta..sub.3 receptors such as cancer,  
 osteoporosis, restenosis, and angiogenic-based diseases.

L9 ANSWER 68 OF 70 USPATFULL  
 ACCESSION NUMBER: 1998:75789 USPATFULL  
 TITLE: Meta-substituted phenylene derivatives  
 INVENTOR(S): Chandrakumar, Nizal, Vernon Hills, IL, United States  
 Chen, Barbara B., Glenview, IL, United States  
 Chen, Helen Y., Livingston, NJ, United States  
 Clare, Michael, Sokie, IL, United States  
 Gasiecki, Alan F., Vernon Hills, IL, United States  
 Haack, Richard A., Chicago, IL, United States  
 Malecha, James W., Libertyville, IL, United States  
 Ruminski, Peter G., Ballwin, MO, United States  
 Russell, Mark A., Gurnee, IL, United States  
 G. D. Searle & Co., Chicago, IL, United States (U.S.  
 corporation)  
 PATENT ASSIGNEE(S):

NUMBER KIND DATE  
 PATENT INFORMATION: US 5773646 19980630  
 APPLICATION INFO.: US 1997-825086 19970327 (8)

NUMBER DATE  
 PRIORITY INFORMATION: US 1996-14464P 19960329 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Geist, Gary  
 ASSISTANT EXAMINER: Davis, Brian J.  
 LEGAL REPRESENTATIVE: Kovacevic, Cynthia S., Williams, Roger A.  
 NUMBER OF CLAIMS: 30  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 4574

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention relates to a class of compounds represented by  
 the  
 Formula I ##STR1## or a pharmaceutically acceptable salt thereof,  
 pharmaceutical compositions comprising compounds of the Formula I, and  
 methods of selectively inhibiting or antagonizing the .alpha..sub.v .beta..sub.3  
 integrin.

L9 ANSWER 69 OF 70 USPATFULL  
 ACCESSION NUMBER: 1998:68993 USPATFULL  
 TITLE: Sevenmer cyclic peptide inhibitors of diseases involving .alpha..sub.v .beta..sub.3  
 INVENTOR(S): Palladino, Michael A., Olivenhain, CA, United States  
 Lee, Bruce A., San Diego, CA, United States  
 Huse, William D., Del Mar, CA, United States  
 Varner, Judith A., Encinitas, CA, United States  
 PATENT ASSIGNEE(S): IXSYS Incorporated, San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5767071		19980616
APPLICATION INFO.:	US 1995-482106		19950607 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Tsang, Cecilia J.		
ASSISTANT EXAMINER:	Borin, Michael		
LEGAL REPRESENTATIVE:	Needle & Rosenberg, P.C.		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1997		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes non-RGD, nine amino acid cyclic peptides that inhibit the function of the integrin receptor, .alpha..sub.v .beta..sub.3.  
 3. These peptides display surprisingly potent antagonist activity despite the lack of the consensus binding sequence Arg-Gly-Asp, and present opportunities for selective targeting to the .alpha..sub.v .beta..sub.3 receptor. Pharmaceutical compositions and methods of use are also disclosed. The therapeutic uses for the inventive peptides include treating diseases involving .alpha..sub.v .beta..sub.3 receptors such as osteoporosis, restenosis, and angiogenic-based diseases, including cancer, arthritis, and diabetic retinopathy.

L9 ANSWER 70 OF 70 USPATFULL  
 ACCESSION NUMBER: 1998:61644 USPATFULL  
 TITLE: Spirocyclic integrin inhibitors  
 INVENTOR(S): Jadhav, Prabhakar Kondaji, Wilmington, DE, United States  
 Smallheer, Joanne Marie, Lendenberg, PA, United States  
 PATENT ASSIGNEE(S): The DuPont Merck Pharmaceutical Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5760029		19980602
APPLICATION INFO.:	US 1997-816580		19970313 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-13539P	19960315 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Grumbling, Matthew V.	
LEGAL REPRESENTATIVE:	Ferguson, Blair Q.	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5723	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to novel heterocycles, including (S)-2-phenylsulfonylamino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino] propionic acid, which are useful as antagonists of the .alpha..sub.v .beta..sub.3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.